Scarica l'app Stockscreener
2.90
1.75%
0.05
Dopo l'orario di chiusura:
2.90
Precedente Chiudi:
$2.85
Aprire:
$2.79
Volume 24 ore:
302.33K
Relative Volume:
0.82
Capitalizzazione di mercato:
$248.18M
Reddito:
$351.37M
Utile/perdita netta:
$-174.01M
Rapporto P/E:
-1.401
EPS:
-2.07
Flusso di cassa netto:
$-126.94M
1 W Prestazione:
+5.84%
1M Prestazione:
+1.75%
6M Prestazione:
-13.95%
1 anno Prestazione:
-21.41%
Intervallo 1D:
$2.79
$2.92
Intervallo di 1 settimana:
$2.71
$2.965
Portata 52W:
$2.455
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Nome
Atea Pharmaceuticals Inc
Settore
Industria
Telefono
857-204-8109
Indirizzo
225 FRANKLIN STREET, BOSTON
Confronta AVIR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
2.90 | 221.65M | 351.37M | -174.01M | -126.94M | -2.07 |
|
ONC
Beigene Ltd Adr
|
241.43 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-13 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Iniziato | Evercore ISI | Outperform |
| 2020-11-24 | Iniziato | JP Morgan | Overweight |
| 2020-11-24 | Iniziato | Morgan Stanley | Overweight |
| 2020-11-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Atea Pharmaceuticals Inc Borsa (AVIR) Ultime notizie
Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com
Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Wells Fargo & Company MN Increases Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals (AVIR) to Release Earnings on Monday - Defense World
Atea reports high efficacy in Phase 2 HCV drug trial By Investing.com - Investing.com Nigeria
Barclays PLC Increases Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus
Atea reports high efficacy in Phase 2 HCV drug trial - Investing.com
Atea Pharmaceuticals Announces Full Results from Phase 2 - GlobeNewswire
Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025 - marketscreener.com
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - Stock Titan
A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com
Atea Pharmaceuticals (AVIR) Organizes HCV Treatment Panel & Announces Q1 Results | AVIR Stock News - GuruFocus
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times
JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com
Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX
Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada
Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP
Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz
Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks
Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks
Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire
Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan
Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World
Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN
Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews
Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com
Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire
Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener
Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan
HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa
Atea Pharmaceuticals Inc Azioni (AVIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):